Early Changes in Body Composition After Cessation of Growth Hormone Therapy in Childhood-Onset Growth Hormone Deficiency

被引:16
作者
Bechtold, Susanne [1 ]
Bachmann, Sara [1 ]
Putzker, Stephanie [1 ]
Dalla Pozza, Robert [1 ]
Schwarz, Hans Peter [1 ]
机构
[1] Univ Munich, Dr Von Haunerschen Kinderspital, Univ Childrens Hosp, Kinderklin & Kinderpoliklin,Div Endocrinol & Diab, D-80337 Munich, Germany
关键词
Body composition; bone density; bone geometry; growth hormone; transition; GH-DEFICIENT; PROXIMAL RADIUS; BONE SIZE; IGF-I; CHILDREN; ADULTS; ADOLESCENTS; TRANSITION; DENSITY; INSULIN;
D O I
10.1016/j.jocd.2011.05.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
At final height, somatic maturity has not been reached yet. We investigated bone and body composition in patients, who completed pediatric growth hormone (GH) treatment at final height. After a mean period of 0.55 +/- 0.17 yr off GH treatment 90 (66 m/24 f) childhood-onset growth hormone deficiency (GHD) patients were reinvestigated for GHD by insulin tolerance testing at a mean age of 17.52 +/- 1.50 yr. Thirty-seven (25 m/12 0 patients remained GH deficient (persistent GHD). Bone and body composition were measured using peripheral quantitative computed tomography of the nondominant forearm. Bone mineral density (BMD) was within normal limits. Total cross-sectional bone area Z-score (0.64 +/- 1.3) was significantly higher as a result of an enlarged medullary cavity Z-score (1.12 +/- 1.2) leading to reduction of cortical thickness Z-score (-1.21 +/- 1.0). Patients with persistent GHD had a significantly higher fat mass (13.3 +/- 8.7 and 6.8 +/- 4.6 cm(2), p < 0.05), which was more pronounced in multiple pituitary hormone deficiency patients. Shortly after cessation of GH treatment in patients treated for childhood-onset GHD age adequate normal BMD and enlarged diaphysis was detectable. Patients with persistent GHD status had a significant higher fat mass.
引用
收藏
页码:471 / 477
页数:7
相关论文
共 32 条
[11]   The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency [J].
Evans, LM ;
Davies, JS ;
Anderson, RA ;
Ellis, GR ;
Jackson, SK ;
Lewis, MJ ;
Frenneaux, MP ;
Rees, A ;
Scanlon, MF .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 142 (03) :254-262
[12]   Currently used growth-promoting treatment of children results in normal bone mass and density.: A prospective trial of discontinuing growth hormone treatment in adolescents [J].
Fors, H ;
Bjarnason, R ;
Wirén, L ;
Albertsson-Wikland, K ;
Bosaeus, I ;
Bengtsson, BÅ ;
Johansson, G .
CLINICAL ENDOCRINOLOGY, 2001, 55 (05) :617-624
[13]   Defining osteopenias and osteoporoses: Another view (with insights from a new paradigm) [J].
Frost, HM .
BONE, 1997, 20 (05) :385-391
[14]  
Gasco V, 2008, EUR J ENDOCRINOL S1, P45
[16]   Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence [J].
Hogler, Wolfgang ;
Shaw, Nick .
CLINICAL ENDOCRINOLOGY, 2010, 72 (03) :281-289
[17]   Discontinuation of growth hormone (GH) treatment:: Metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects [J].
Johannsson, G ;
Albertsson-Wikland, K ;
Bengtsson, BÅ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (12) :4516-4524
[18]   THE EFFECTS OF ESTROGEN PRIMING AND PUBERTY ON THE GROWTH-HORMONE RESPONSE TO STANDARDIZED TREADMILL EXERCISE AND ARGININE-INSULIN IN NORMAL GIRLS AND BOYS [J].
MARIN, G ;
DOMENE, HM ;
BARNES, KM ;
BLACKWELL, BJ ;
CASSORLA, FG ;
CUTLER, GB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (02) :537-541
[19]   Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: A phase III multicenter, double-blind, randomized two-year trial [J].
Mauras, N ;
Pescovitz, OH ;
Allada, V ;
Messig, M ;
Wajnrajch, MP ;
Lippe, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (07) :3946-3955
[20]   Alterations in the oxidant-antioxidant status in prepubertal children with growth hormone deficiency: effect of growth hormone replacement therapy [J].
Mohn, A ;
Di Marzio, D ;
Giannini, C ;
Capanna, R ;
Marcovecchio, M ;
Chiarelli, F .
CLINICAL ENDOCRINOLOGY, 2005, 63 (05) :537-542